Clinical Trial News and Research

RSS

Vibration-based technology reduces apneic events, improves critical clinical parameters in premature infants

Scientists and clinicians at the University of Massachusetts Medical School, Wyss Institute for Biologically Inspired Engineering, and the Beth Israel Deaconess Medical Center have shown in a clinical trial that a new, vibration-based prevention technology tested in a neonatal intensive care unit (NICU) reduces apneic events and improves critical clinical parameters in prematurely born infants.

24 Nov 2015

Mason researchers patent new breast cancer treatment

George Mason University researchers have patented a new breast cancer treatment that uses a common malaria drug to stop cancer in its beginning stages.

21 Nov 2015

New drug screening method may predict treatment options for patients with multiple myeloma

A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer. The process, developed by scientists at Washington University School of Medicine in St. Louis, also may aid patients with leukemia or lymphoma.

21 Nov 2015

TVA Medical announces results from multicenter clinical study of everlinQ endoAVF System

TVA Medical, Inc., announced clinical trial results from a prospective, multicenter clinical study evaluating the everlinQ endoAVF System. This innovative medical technology creates hemodialysis access using vascular sites not traditionally used by surgeons for people with end-stage kidney disease (ESKD).

21 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

ProMetic Life Sciences Inc. announced today that it has entered into a strategic partnership with ProThera Biologics Inc. for the development and commercialization of human plasma-derived Inter-alpha Inhibitor Proteins.

19 Nov 2015

University of York researchers unveil 3-D structure of cancer target enzyme

A team from the University of York has published research unveiling the 3-D structure of human heparanase, a sugar-degrading enzyme which has received significant attention as a key target in anti-cancer treatments.

19 Nov 2015

New drug combination may reduce need for complex regimens to treat hepatitis C

The prognosis for people with hepatitis C has improved dramatically in the last few years, thanks to the introduction of direct-acting anti-viral medications, including Harvoni (the brand name for a combination of ledipasvir and sofosbuvir) and Viekira Pack (a mix of ombitasvir, paritaprevir, ritonavir and dasabuvir).

19 Nov 2015

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published in the latest issue of the journal Lancet Infectious Disease.

19 Nov 2015

Scientists identify mechanism that may help prostate cancer cells escape effects of cancer drugs

Advanced prostate cancer is a disease notoriously resistant to treatment. New research by scientists at Fred Hutchinson Cancer Research Center and the University of California, San Francisco sheds light on a new mode of drug resistance to emerging therapies in metastatic prostate cancer.

18 Nov 2015

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

UCLA researchers find new way to reduce ascites with minimal side effects

Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. The most common treatment for ascites is puncturing the abdomen and manually draining the fluid, which is painful and risky and must be repeated every few weeks.

18 Nov 2015

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

Respiratory infections are common in preschoolers, but while most children recover fairly easily from the typical coughs and congestion, a significant number develop illnesses severe enough to interfere with breathing and warrant trips to urgent care clinics or emergency rooms.

18 Nov 2015

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

$HSS researchers study outcomes of novel implant in patients undergoing wrist fracture surgery$

HSS researchers study outcomes of novel implant in patients undergoing wrist fracture surgery

Researchers at Hospital for Special Surgery have launched a study to determine if a novel implant allowing for less invasive surgery for a broken wrist leads to a quicker recovery, less post-operative pain and fewer complications compared to conventional surgical treatment.

17 Nov 2015

Study: Safe spaces may play critical role in community-based HIV prevention efforts

The creation and sustainment of "safe spaces" may play a critical role in community-based HIV prevention efforts by providing social support and reducing environmental barriers for vulnerable populations, a new study from an Oregon State University researcher has found.

17 Nov 2015

Clinical Trial News and Research

Vibration-based technology reduces apneic events, improves critical clinical parameters in premature infants

Mason researchers patent new breast cancer treatment

New drug screening method may predict treatment options for patients with multiple myeloma

TVA Medical announces results from multicenter clinical study of everlinQ endoAVF System

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Hapten Sciences plans to initiate Phase 1 clinical trial for new poison ivy vaccine

Lilly, Merck expand oncology clinical trial collaboration

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

University of York researchers unveil 3-D structure of cancer target enzyme

New drug combination may reduce need for complex regimens to treat hepatitis C

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

Scientists identify mechanism that may help prostate cancer cells escape effects of cancer drugs

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

UCLA researchers find new way to reduce ascites with minimal side effects

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

HSS researchers study outcomes of novel implant in patients undergoing wrist fracture surgery

Study: Safe spaces may play critical role in community-based HIV prevention efforts

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer